Abstract
There is increasing impetus to begin disease-modifying therapy for relapsing multiple (R-MS) early, before the development of irreversible tissue damage and resultant permanent disability. However, all of the currently-approved therapies for relapsing multiple sclerosis are only partially effective for patients as a group. Treatment failure can be due to noncompliance with therapy, intolerable adverse effects, the development of neutralizing antibodies, or non-responsive disease. Neurologists managing patients on disease-modifying therapy for R-MS must remain vigilant for these issues and take appropriate action when necessary. Copyright (C) 1999 Elsevier Science B.V.
Original language | English (US) |
---|---|
Pages (from-to) | 29-36 |
Number of pages | 8 |
Journal | Journal of neuroimmunology |
Volume | 98 |
Issue number | 1 |
DOIs | |
State | Published - Jul 1 1999 |
Keywords
- Adverse effects
- Combination therapy
- Compliance
- Magnetic resonance imaging
- Neutralizing antibodies
- Treatment failure
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Neurology
- Clinical Neurology